Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression.
Adoptive cellular immunotherapy, infusions of interleukin 2 (IL-2) in conjunction with in vitro-activated killer cells, has brought new hope to patients with cancer. The broad application of this strategy, however, is constrained by the need for repeated leukapheresis and by the labor-intensive proc...
Guardat en:
| Publicat a: | Proc Natl Acad Sci U S A |
|---|---|
| Autors principals: | , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
National Academy of Sciences
1994
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC44509/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8058730/ https://ncbi.nlm.nih.govhttps://doi.org/10.1073/pnas.91.17.7889 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|